ASXL1 and cyclic hematopoiesis: Based on targeted sequencing (with VAF ≥ 1% sensitivity; Supplementary Table 3)27, we selected 12 individuals with known CH drivers (6 with DNMT3A, 4 TET2, 1 ASXL1 and 1 with both TET2 and ASXL1 mutations), and 10 individuals without known drivers.